Semax

Semax API is a synthetic peptide derived from the adrenocorticotropic hormone (ACTH) fragment, consisting of seven amino acids with the sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). It was originally developed in Russia for research in neuroprotection, cognitive enhancement, and central nervous system regulation. Semax is notable for its stability compared with endogenous ACTH fragments and for its ability to cross the blood–brain barrier, making it a valuable compound in neuroscience research.

The API is supplied as a high-purity, lyophilized white or off-white powder. It is produced under strict quality control standards and characterized by HPLC and mass spectrometry to confirm identity and purity, which is typically ≥99% by HPLC. Each batch can be accompanied by a Certificate of Analysis (COA) to ensure consistency and reliability for laboratory and analytical applications. Semax API is commonly offered in milligram-scale quantities suitable for research, formulation development, and reference studies.

In experimental settings, Semax is widely studied for its effects on neurotrophic factor expression (including BDNF), cognitive performance, memory formation, attention, and neuroprotective mechanisms, particularly under conditions of stress or ischemic models. Unlike classical stimulant or sedative compounds, Semax is reported in research literature to exert its effects without significant sedation or motor impairment, which enhances its appeal for mechanistic studies.

Semax API is not approved as a pharmaceutical drug or dietary supplement in most jurisdictions and is intended strictly for research and laboratory use only. It is not for human or clinical application. For optimal stability, the lyophilized product should be stored in a cool, dry, and light-protected environment. Reconstituted solutions should be handled carefully and stored for limited periods to maintain peptide integrity.